---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-028305"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2023-04-07T23:59:59+00:00"
generated_at: "2026-06-17T04:46:24.603829+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nasdaq notifies Phoenix Biotech of MVLS non-compliance for 30 consecutive days

## Summary
- Received Nasdaq letter on April 3, 2023; common stock MVLS below $50M minimum for 30 consecutive trading days.
- Has 180 days (until October 2, 2023) to regain compliance under Listing Rule 5810(c)(3)(C).
- To regain compliance, MVLS must close at or above $50M for at least ten consecutive business days.
- If not compliant by deadline, may transfer to Nasdaq Capital Market or face delisting with appeal rights.
- Deficiency notice has no immediate effect on listing or trading; Company monitoring options.

## SEC filing metadata
- accession: 0001213900-23-028305
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2023-04-07T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390023028305/0001213900-23-028305-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390023028305/ea176568-8k_phoenix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-028305
- JSON: https://secwatch.observer/filing/0001213900-23-028305.json
- Plain text: https://secwatch.observer/filing/0001213900-23-028305.txt

## Key facts
- Listing & Compliance Notices
  CERO THERAPEUTICS HOLDINGS, INC. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5450(b)(2)(A)
  source text: April 3, 2023, Phoenix Biotech Acquisition Corp., a Delaware corporation (the “ Company ”), received a letter (the “ Letter ”) from the staff at The Nasdaq Global Market (“ Nasdaq ”) notifying the Company that, for the 30 consecutive trading days prior to the date of the Letter, the Company’s common stock had traded at a value below the minimum $50,000,000 “Market Value of Listed Securities” (“ MVLS ”) requirement set forth in Nasdaq Listing Rule 5450(b)(2)(A), which is required for continued listing of the Company’s common stock on Nasdaq. The Letter is only a notification of deficiency, not
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390023028305/0001213900-23-028305-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.